Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC

American Journal of Clinical Pathology

Volumn 137, Issue 6, 2012, Pages 978-985

  Zhuang, Xuewei ^a,b   Zhang, Xiaoning ^a   Xia, Xiyan ^b   Zhang, Cuijuan ^b   Liang, Xiaohong ^a   Gao, Lifen ^a   Zhang, Xin ^a   Ma, Chunhong ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Prognosis; Survival rate; T cell immunoglobulin mucin domain 3

Indexed keywords

MEMBRANE PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 CONTAINING MOLECULE 3 PROTEIN; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; CANCER STAGING; KAPLAN MEIER METHOD; LUNG TUMOR; LYMPHOCYTE; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TIME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; TIME FACTORS;

EID: 84864214537     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP9Q6OVLVSHTMY     Document Type: Article

References (31)

1. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536-541. (Pubitemid 34130609)
2. Jones RB, Ndhlovu LC, Barbour JD, et al. TIM-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763-2779.
3. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of TIM-3 and TIM-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102-1110. (Pubitemid 37428038)
4. Oikawa T, Kamimura Y, Akiba H, et al. Preferential involvement of TIM-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol. 2006;177:4281-4287. (Pubitemid 44469756)
5. Bruck P, Ramos-Lopez E, Bartsch W, et al. TIM-3 polymorphisms in type 1 diabetes families. J Hum Genet. 2008;53:559-564.
6. Yang L, Anderson DE, Kuchroo J, et al. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008;180:4409-4414.
7. Khademi M, Illes Z, Gielen AW, et al. T Cell Ig- and mucin-domain- containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 2004;172:7169-7176. (Pubitemid 38669161)
8. Wiener Z, Kohalmi B, Pocza P, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 2007;127:906-914. (Pubitemid 46434647)
9. Houwen L. State of the art: lung cancer in China. Ann Thorac Cardiovasc Surg. 2003;9:147-148.
10. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006;130:1211-1219. (Pubitemid 44583755)
11. Carney DN. Lung cancer: time to move on from chemotherapy. N Engl J Med. 2002;346:126-128. (Pubitemid 34438905)
12. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17(suppl 1):S37-S58. (Pubitemid 127673771)
13. Pence JC, Kerns BJ, Dodge RK, et al. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg. 1993;128:1382-1390. (Pubitemid 23360034)
14. Miyoshi T, Kondo K, Hino N, et al. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res. 1997;3:1289-1297. (Pubitemid 27362389)
15. Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995;55:5038-5042.
16. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998;16:2468-2477. (Pubitemid 28309043)
17. Hsu JT, Barrett CR Jr. Lung abscess complicating transbronchial biopsy of a mass lesion. Chest. 1981;80:230-232. (Pubitemid 11051805)
18. Kayser B, Sliwinski P, Yan S, et al. Respiratory effort sensation during exercise with induced expiratory-flow limitation in healthy humans. J Appl Physiol. 1997;83:936-947. (Pubitemid 27392316)
19. Hastings WD, Anderson DE, Kassam N, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol. 2009;39:2492-2501.
20. Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821-3830.
21. Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141-1143. (Pubitemid 350134897)
22. Ju Y, Hou N, Meng J, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 2010;52:322-329.
23. Wang F, He W, Zhou H, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol. 2007;250:68-74.
24. Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093-1101. (Pubitemid 37428037)
25. Nakae S, Iikura M, Suto H, et al. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood. 2007;110:2565-2568. (Pubitemid 47523180)
26. Hasegawa Y, Takanashi S, Kanehira Y, et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964-971.
27. Colasante A, Mascetra N, Brunetti M, et al. Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. Am J Respir Crit Care Med. 1997;156:968-973. (Pubitemid 27396443)
28. Ju Y, Hou N, Zhang XN, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009;6:35-43.
29. Huang X, Bai X, Cao Y, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med. 2010;207:505-520.
30. Yasumoto K, Takeo S, Yano T, et al. Role of tumorinfiltrating lymphocytes in the host defense mechanism against lung cancer. J Surg Oncol. 1988;38:221-226.
31. Zhuang X, Xia X, Wang C, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010;18:24-28.